INTRODUCTION
============

The transformation of normal lung tissue into lung adenocarcinomas involves, among other characteristic features, a hallmark process by which the cell loses control of its replication process (an accelerated cell cycle) ([@b1]). Adenocarcinomas have a high incidence of fatality in patients in US, and a similar trend is developing in other countries ([@b2]). At present, lung cancer studies generally incorporate two main objectives: providing an early and sensitive diagnosis, and trying to understand the molecular basis underlying the disease formation. Recently, the availability of the human genome sequence ([@b3]) and gene expression profiling techniques ([@b4]) have provided new insights, narrowing the gap to achieve these objectives. The challenges that lie ahead include systematically identifying the functions of all cancer associated genes, and continuing the efforts to decipher their regulatory networks. This information will provide a much deeper understanding of the mechanism of cancer cell formation and development, and assist in the identification of potent therapeutic targets for disease control and eradication.

Computational methods that are employed to identify cancer associated genes from megabytes of noisy microarray data still require further development. Data normalization procedures may have an important effect on the succeeding downstream data analysis ([@b5]--[@b8]). Using human housekeeping genes as the least variable set of gene expression profiles is one accepted method ([@b9]). Many computational methods have been introduced to determine marker genes for cancer from gene expression datasets ([@b10],[@b11]). These methodologies aim to stratify samples into tissue classes or phenotypes based on the ability of sets of differentially regulated genes to discriminate among the samples. Methods such as recursive partitioning ([@b12]), expression ratio analysis ([@b13]), principal component analysis ([@b14]), partial least squares ([@b15]), and independent component analysis ([@b16]) have been used to identify the minimum set of genes that can achieve this classification. However, the usually small number (tens) of (tissue) samples per class and the large number (tens of thousands) of features (genes) in these datasets cast doubt on the statistical significance of genes identified as discriminating between normal or cancer tissues or cancer subtypes. The effects on the detection of cancer marker genes due to these constraints, which can lead to genes being classified as markers by chance, have been investigated ([@b17]).

Recently, the use of computational methods to identify regulatory elements has become increasingly important ([@b18]). This is partly because the alternative of experimental determination of cis-regulatory elements can be inaccurate, and is often slow and laborious ([@b19]). A common way to analyze regulatory relationships among genes using microarray data is to cluster the genes, based on their expression profiles, into sets of putatively co-regulated genes. This assumes that co-regulated genes are likely to have cis-regulatory elements in common ([@b20]). However, searching for common sequence signals in genomic regions near these genes can lead to the detection of spurious cis-regulatory elements, as many genes may show similar expression profiles for reasons other than co-regulation ([@b20]). Many studies have shown that biologically relevant cis-regulatory elements often occur in groups ([@b21],[@b22]). Following this rationale, conserved regulatory motifs correlated to gene expression were discovered by fitting a linear regression model to the expression arrays from *Saccharomyces cerevisiae* ([@b23]) and an extension of this technique was used to identify binding motifs of the transcription factors ROX1p and YAP1p ([@b24]). In this work, we performed a microarray based study of a set of normal lung tissues and a set of primary lung adenocarcinomas. Our aims were, first, to distinguish the broadest set of genes (*M*~AD~) that showed differential expression levels across the two tissue types and investigate the correlation of their gene expression profiles with the tissue type. Second, we wished to examine the division of genes with the same functional annotation between the *M*~AD~ set and the remaining genes on the microarray to find functional groups disproportionately represented in *M*~AD~. Finally, we attempted to identify the transcription factors, as well as their corresponding binding sites, which regulate the observed expression differences of the genes in the *M*~AD~ set.

The rationale for the first two aims was that, we could make use of the knowledge accumulated by scientists on genes in the *M*~AD~ set, by using functional annotations assigned through Gene Ontology terms, to investigate the nature of the biological processes that were actually perturbed in cancer cells. It was expected that some functional classes would preferentially be found in the *M*~AD~ gene set. Instead of clustering genes based solely on their expression profiles, genes were first selected by sharing a gene ontology term and then clustered by an expression profile. The reasoning behind this was that genes with the same function and similar expression profiles were more likely to be under the same regulatory control than genes with differing functions but similar expression profiles. 'In biblio' analysis of genes\' neighborhoods has been long advocated as an efficient means to permit inductive reasoning by using the knowledge accumulated by the worldwide community of researchers ([@b25]). A motif finding algorithm developed by us, MoDEL ([@b26]), was used to discover highly conserved DNA regions associated with the genes in a cluster, before these sequences were scanned against the TRANSFAC 8.3 database to detect plausible oncogenic transcription factor binding sites.

MATERIALS AND METHODS
=====================

Primary lung adenocarcinoma dataset
-----------------------------------

Tissue samples for the complete cohort of this study were collected, with informed consent, by the Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong. A total of 58 patients gave samples with normal lung tissue (*n* = 9) and primary lung adenocarcinomas (*n* = 49). Identifier code numbers were assigned to each tissue sample and its correlated clinical data. The link between the code numbers and all patient identifiers was destroyed, rendering the samples and clinical data completely anonymous. Clinical data from hospital records included the age and sex of the patient, smoking history, type of resection, post-operative pathological staging, post-operative histopathological diagnosis, patient survival information, time of last follow-up interval or time of death (when known), and site of disease recurrence (when known). Information for the entire dataset is provided as Supplementary Material at <http://bioinfo.hku.hk/~daniely/lung_microarray/>. It is noted that the numbers do not always add to 58, as complete information could not be found for all samples.

The gender composition of the cohort was 25 males and 33 females. The reported smoking history of the patients was 24 non-smokers, 10 smoking at least 40 packs per year, seven ex-smokers and nine passive smokers. Post-operative pathological staging of these samples revealed 26 stage I, 8 stage II, 14 stage III and 1 stage IV tumors.

Tissue samples were snap-frozen in liquid nitrogen within 30 min after dissection and kept at −70°C until use. Tumor samples were examined before use to ensure at least 70% of tumor by area. RNA was extracted following standard protocols and hybridized to Affymetrix HG-U133A GeneChips. Expression values from a total of 22 283 transcript probe sets were collected using Affymetrix scanners and analysis software (Microarray Suite 5.0.1). The raw dataset is publicly available at ArrayExpress (public repository for microarray data [www.ebi.ac.uk/arrayexpress;](www.ebi.ac.uk/arrayexpress;) accession number: E-MEXP-231) ([@b27],[@b28]); or can be downloaded at <http://bioinfo.hku.hk/~daniely/lung_microarray/>.

Data re-scaling and feature selection
-------------------------------------

The raw expression data from each sample was rescaled (normalized) to account for systematic differences in signal intensities among the microarrays, using standard procedures in Affymetrix Microarray Suite 5.0.1. Expression values from each microarray were multiplied by a scaling factor to make the average intensity of a set of house keeping genes on each microarray equal to an arbitrarily defined target intensity of 500.

To identify genes that are tissue phenotype related, the mean expression level of all genes in normal tissues and in adenocarcinoma tissues were calculated. If the ratio of the average expression levels of a gene between the two tissue classes exceeded 2-fold, the genes were included in the set *M*~AD~.

Gene to tissue correlation
--------------------------

The tissue type distinction is represented by an idealized expression pattern (a vector with size 1 × 58), in which the expression is labeled uniformly high (value = 1) in adenocarcinoma tissue type and labeled uniformly low (value = 0) in normal tissue class. Correlation coefficients were calculated for the comparison of this vector with the expression profiles of each gene in *M*~AD~. The distribution of correlation coefficients was counted in bins of 0.2. The result was compared to the corresponding distribution obtained for ten random permutations of the idealized tissue labels to give the average random correlation coefficients for each gene ([Figure 1](#fig1){ref-type="fig"}).

Determination of overrepresentation of gene ontology terms in the set *M*~AD~
-----------------------------------------------------------------------------

GeneOntology (<http://www.geneontology.org/>) terms, which classify a gene according to its molecular function, biological process, cellular component and chromosomal localization, were collected for each gene on the Affymetrix HG-U133A microarray from the Affymetrix library files. By using the hypergeometric distribution ([Equation 1](#e1){ref-type="disp-formula"}), genes with each of these functional annotations could be assessed to see if they are overrepresented in the set *M*~AD~. Given *G* annotated genes on a microarray, of which *A* have a certain function (gene ontology term), and a set of *k* genes selected independently of the functional annotations (*M*~AD~), the probability that *n* or more of the set of k genes have this function can be calculated by [Equation 1](#e1){ref-type="disp-formula"} ([@b23]). If the *P*-value of observing the number of genes with a particular gene ontology term in the set *M*~AD~ was \<0.001, the term was considered to be significantly overrepresented in the set *M*~AD~. DNA-Chip Analyzer (dChip) ([@b29]) was used to perform this task. $$p = \sum\limits_{i = n}^{\min\lbrack k,A\rbrack}\frac{\begin{pmatrix}
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Constructing gene relationship trees for overrepresented gene ontology terms
----------------------------------------------------------------------------

For all possible combinations of gene pairs that belong to each gene ontology term overrepresented in *M*~AD~ the correlation coefficient, *r*, of their expression profiles was calculated. A pairwise gene distance matrix *M*~distance~, using the distance 1-*r* was formed for the genes. The neighbor-joining algorithm (NJ) ([@b30]) was used to construct a gene relationship tree from pairwise gene distance matrix. This was performed to identify gene neighbors whose expression values followed a common trend. The NJ algorithm is a special case of the star decomposition method. Starting from a star tree, the final relationship tree is constructed systematically by linking the least distant pair of nodes (genes in this case). The main advantage of the algorithm is that it permits lineages with largely different branch lengths. The programming script for computing *r* was implemented in the MatLab technical programming language and the tree was calculated using MEGA2 ([@b31]).

Extraction of the upstream regions for putatively co-regulated gene sets
------------------------------------------------------------------------

Putatively co-regulated genes from each gene ontology term that was overrepresented in *M*~AD~ were selected in accordance with two criteria: (i) a distance metric cutoff value (*d~i,j~* \< 0.20) for all pairwise gene distances within the selected *N* members of the gene set; and (ii) the minimum mean aggregated pairwise distances \[$$\] for the selected *N* members of the gene set. The rationale for choosing these criteria was to find a single most correlated gene cluster that minimizes the total branch length *d~i,j~*. For instance, if there are two gene clusters (each constituted of four and five gene members, respectively) in the tree topology found to be satisfying criterion one, i.e. get sets in which all pairwise gene distances (^4^C~2~ = 6 and ^5^C~2~ = 10 distances, respectively) satisfy the distance metric cutoff value \<0.2, the final gene set selected should be the one with the minimum mean aggregated pairwise distances (criterion two). As a result, a different numbers of genes will be selected from each gene ontology term based on these criteria. For each of the selected genes, the corresponding 5 kb region located directly upstream of the transcription start site was extracted as described previously ([@b32]). Several sequence features including sequence gaps, continuity, consistency between the two distinct drafts of human genomes ([@b3],[@b33],[@b34]) were taken into consideration. Detailed information can be found in ([@b32]).

Identification of conserved regions and detection of associated transcription factors
-------------------------------------------------------------------------------------

All 5 kb unaligned DNA sequences associated with each gene ontology term group overrepresented in *M*~AD~, were searched using MoDEL ([@b26]), to reveal possible highly conserved DNA regions. MoDEL employs an evolutionary algorithm and hill-climbing optimization for global and local exploration of two targeted search spaces, respectively (all possible words and all possible ungapped local multiple alignments). This heuristic algorithm has been shown to have more efficient optimization capabilities than other motif discovery tools ([@b26]). The word size was set to be 50 bp in the present study because we found that the conserved regions identified by MoDEL remained rather consistent with different sizes of word or segment length. A 50 bp segment length (the longest implemented in MoDEL) also allows a larger window, whereby the most conserved motifs can be captured together with their less similar surrounding residues. The information content for all conserved regions identified was calculated based on the Kullback--Leibler divergence (relative entropy).

All conserved regions identified by MoDEL were scanned against all vertebrate transcription factor position weight matrix profiles contained in the TRANSFAC database version 8.3 ([@b35]) to identify all previously known transcription binding sites. To incorporate stronger matches of transcription factor binding sites, stringent settings for the Match program ([@b36]) were employed. Both the core matrix and overall matrix similarity were required to be least 0.9 to be considered a match.

RESULTS
=======

Selection of the cancer associated gene set *M*~AD~
---------------------------------------------------

A total of 3442 genes were found to be either up- or down-regulated by more than 2-fold between the normal and adenocarcinoma tissue sets ([Table 1](#tbl1){ref-type="table"}). These genes formed the cancer associated gene set *M*~AD~. Of these genes, 1294 showed down-regulation and 2148 showed up-regulation of gene expression levels in adenocarcinomas. At the extreme ends of the fold change range, the receptor for advanced glycation end product (RAGE) was found to be repressed by \>32-fold in adenocarcinomas while the D G antigen (GAGED2) was found to be up-regulated by \>128-fold. Real-time quantitative RT--PCR analysis (Supplementary Materials) to verify the mRNA transcript levels for carbonic anhydrase IV (CA4) and RAGE were performed in 14 independent tissue samples (seven samples from each tissue phenotype). The abundance of mRNA transcripts for both genes was extremely low in the adenocarcinoma samples. If a gene is not expressed or expressed at very low levels in a sample, then fold change values may become large due to the low denominator. Fold change values must be considered in conjunction with expression levels.

Functional annotation groups significantly overrepresented in *M*~AD~
---------------------------------------------------------------------

Down- and up-regulated genes in *M*~AD~ were treated separately to detect functional annotation groups that may be overrepresented in adenocarcinoma associated genes. [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, respectively, give the gene ontology terms significantly overrepresented (*P* \< 0.001) in down- and up-regulated genes of *M*~AD~. The tables give the number of genes with that gene ontology term on the HG-U133A microarray, the number found, and the *P*-value of finding at least that number of genes (by random chance) in *M*~AD~.

For genes down-regulated in adenocarcinomas, several gene ontology terms related to immune responses were overrepresented, indicating that there appeared to be a depression in defense mechanisms in general, for the adenocarcinoma tissue samples ([Table 2](#tbl2){ref-type="table"}). In addition, genes associated with 'signal transducer activity' (e.g. TEK tyrosine kinase, G protein-coupled receptor kinase) were also identified to be significantly overrepresented in down-regulated genes in *M*~AD~, suggesting the blockage of signal transduction genes in adenocarcinoma cells. Many gene ontology terms that were overrepresented in the up-regulated genes of *M*~AD~ were associated with the cell cycle and cell replication machinery ([Table 3](#tbl3){ref-type="table"}) as might be expected from accelerated cancer cell proliferation.

Construction of relationship trees and determination of putatively co-regulated genes
-------------------------------------------------------------------------------------

After obtaining the constituent member genes for each gene ontology term overrepresented in *M*~AD~, we investigated their pairwise gene expression relationships. Supplementary Material figure 2 shows an example of such a study for the gene ontology term 'DNA replication and chromosomal cycle' with the GenBank accession numbers for each tree branch corresponding to the genes in *M*~AD~ that are assigned this ontology term. The branch distances displayed were used to derive the putatively co-regulated gene set (marked by an asterisk) according to the two criteria stated in the Materials and Methods section. In this example, the putatively co-regulated genes were: (i) MCM2---mini-chromosome maintenance deficient 2; (ii) replication factor C (activator 1) 4; and (iii) CDC45---cell division cycle 45-like.

Identification of conserved DNA motifs and transcription factors associated with a GO term
------------------------------------------------------------------------------------------

Conserved regions, within 5 kb of the transcription start site, of the putatively co-regulated genes associated with each gene ontology term overrepresented in *M*~AD~ were identified using MoDEL ([@b30]). Example results from four gene ontology terms: (i) DNA replication and chromosomal cycle; (ii) nuclear division; (iii) cellular defense response and (iv) signal transduction, are shown in [Table 4](#tbl4){ref-type="table"}. The first two terms are associated with genes that were up-regulated in adenocarcinoma tissues, whereas the latter two terms are associated with down-regulated genes. Conserved regions are presented using IUPAC uncertainty codes, with highly conserved residues shown in bold, along with their start position relative to the transcription start site. The occurrence of each of these 50mers in regions 5 kb upstream of all human genes ([@b32]) is shown along with the proportion of those genes that have the same GO term and regulation pattern of the gene in the table. The final column reports the transcription factors (from TRANSFAC 8.3) that may bind to the conserved region based on matches to their binding site motifs. The complete data for [Table 4](#tbl4){ref-type="table"} can be found at <http://bioinfo.hku.hk/~daniely/lung_microarray/>.

DISCUSSION
==========

This study first identified a large set of genes (*M*~AD~) showing a 2-fold differential behavior in adenocarcinoma cells when compared with normal lung tissue. Of these genes, 2528 genes (73.45%) were also identified passing the *t*-test criteria (*P* \< 0.005, complete *t*-test gene list available at <http://bioinfo.hku.hk/~daniely/lung_microarray/>). Transcription factors with binding site motifs that matched conserved DNA regions upstream of genes in *M*~AD~ were then identified, as these may be the factors that regulate the oncogenic process. This was achieved by incorporating both experimentally determined gene expression data and bioinformatic tools. Below, we will discuss the functional annotation groups (gene ontology terms) that were overrepresented in the cancer associated genes and their putative regulatory transcription factors. Only some salient findings can be presented due to the size of the dataset and full details are provided as Supplementary Material.

In a separate study, we identified 88 lung cancer associated genes (data not shown) from our microarrays, using a feature partitioning method we developed earlier ([@b37]). However, here, we aimed to identify the broadest set of cancer associated genes (*M*~AD~) by using fold-ratio analysis, and to examine their functional annotations in order to understand the biological processes that are altered in cancer when compared with normal tissue. A broad gene set was important to ensure statistical validity when determining the functional groups (gene ontology terms) that were overrepresented in the gene population in *M*~AD~. More than three thousand genes were found to be up- or down-regulated by \>2-fold and all 88 cancer associated genes identified using the earlier method ([@b37]) were found in this set.

In previous works ([@b38]--[@b40]), differential gene expression in cancer was reported but relatively little elaboration of the genes\' functions, or the regulatory cascades and biological processes underlying the observations was made. Here, we found that many gene ontology terms disproportionately occurred (*P* \< 0.001) among the sets of genes that were either substantially up- or down-regulated in adenocarcinomas. This gave evidence of the systematic up- or down-regulation of several biological processes directly linked to oncogenesis. Such processes included increased cell multiplication, angiogenesis, vascularization, and glucose and amino acid metabolism.

Glucose metabolism is crucial because cancer cell growth depends on glucose availability, rather than respiration, for biomass construction ([@b41]). Increased expression of glycolytic enzymes, including pyruvate carboxylase, citrate synthase, aconitate hydratase, oxalosuccinate decarboxylase, glucose-6-phosphate isomerase, fructose-bisphosphate aldolase, glucose transporter (GLUT) and [l]{.smallcaps}-lactate dehydrogenase were observed in the microarray data. This is consistent with the fermentation metabolism (needed for ATP synthesis in the absence of efficient respiration), and with entry into a tricarboxylic acid pathway for glutamate and aspartate synthesis (i.e. biomass construction) rather than respiration.

Unlike mostly resting normal cells, where oxygen is used in oxidative phosphorylation for ATP synthesis and cell maintenance, cancer cells metabolize glucose at a much higher rate, in order to generate ATP and use pyruvate as the substrate to generate lactate to replete the NAD pool (Warburg\'s effect), while stopping the cycling of the tricarboxylic acid pathway ([@b42],[@b43]). The major outcome of this metabolic shift is, by preventing the tricarboxylic acid pathway cycling, to produce biomass rather than energy. This effect, overlooked for some time, was discovered \>70 years ago ([@b41]). Much effort has been initiated to identify the transcription factor(s) that facilitate this change of course in cancer cells (from aerobic slow growth or resting state into anaerobic use of glucose while growing) by up-regulating the expression and activity of all enzymes directly related to this essential metabolic pathway. In recent publications, several transcription factors \[hypoxia inducible factor 1 (HIF-1) ([@b44]); Myc ([@b45]); Ras ([@b46]); v-SRC([@b47]); p53([@b48]) and pVHL([@b49])\] were reported to play a role in the regulation of the expression of these glycolytic enzymes.

From the genes in *M*~AD~ associated with each overrepresented gene ontology term, a subset of genes with more consistent expression profiles was identified and the upstream regions of these genes were searched for conserved elements. Such conserved DNA regions, if they exist, are likely to be evolutionarily significant ([@b50]--[@b54]). Wasserman *et al*. ([@b55]) showed that a large proportion (\>98%) of experimentally defined transcription factor binding sites are restricted to the most conserved residues within their own promoter regions. Earlier studies have used databases such as TRANSFAC to search for transcription factor binding sites in the upstream regions of genes; however, this can lead to many false positives ([@b56],[@b57]). Clustering of genes based on expression profiles has been used to select sets of genes more likely to be co-regulated ([@b20]); however, with increasing numbers of genes in the clusters, the number of false positive identifications increases. One reason for this is the inclusion of genes in the cluster that are not actually co-regulated, hampering the correct detection of conserved DNA regions by most motif discovery tools ([@b21],[@b22]). Methods to evaluate putative regulatory sites and newly detected motifs have also been proposed ([@b58]).

To address this issue, we combined the gene expression correlation coefficients and gene functional classes of all the cancer-associated genes (*M*~AD~) to select a more consistent set of likely co-regulated genes. These genes not only had a consistent expression pattern with the highest possible pairwise gene correlation, but also shared the same functional role. No limit was placed on the number of genes that would be selected from each functional group, and all genes with expression profiles within a cutoff value (*d* \< 0.20) were selected. These criteria were motivated by there being many examples, which show that transcription factors have multiple target genes, of which a significant portion is involved in a common metabolic pathway. For instance, the CAP transcription factor in *Escherichia coli* has been shown to mediate the regulation of dozens of genes involved in glucose metabolism ([@b59],[@b60]). In humans, the GATA binding protein 1 (globin transcription factor 1, GATA-1) plays an important role in erythroid development by regulating hemoglobin production ([@b61]). The majority of genes that are regulated by this transcription factor contain the gene ontology term 'hemoglobin'. Moreover, growth factor independent 1 (Gfi-1) acts on a subset of genes involved in the differentiation of the hematopoietic lineage ([@b62]).

MoDEL, the motif discovery program used here, has been demonstrated extensively and compared with other existing motif finding algorithms by analyzing sets of complex natural amino acid sequences (e.g. HTH protein motifs) and artificial datasets (planted motifs) ([@b26]). It was shown to have a more efficient optimization method than other local multiple alignment methods. Unlike algorithms that search for motifs by exhaustive enumeration of overrepresented words ([@b63]), MoDEL looks for a set of conserved occurrences based on information content ([@b26]). The objective of MoDEL is to identify exactly one occurrence per sequence in such a way that all chosen occurrences are maximally similar across the sequence set. A validation of MoDEL on the CAP-mediated gene set ([@b59]) in bacteria successfully extracted the conserved regions that incorporate the CAP binding sites (Supplementary Material).

Having identified conserved DNA regions associated with genes with the same functional annotation and similar expression profiles, *in silico* pattern-based scanning against the TRANSFAC 8.3 database for transcription factors with binding site motifs in these conserved DNA regions was performed. Among the transcription factors identified as putative regulatory factors for these genes ([Table 4](#tbl4){ref-type="table"}), some had been reported in previous publications to promote or suppress cancer formation, whereas the remaining transcription factors have generally not been sufficiently characterized *in vivo*. Four of these appear to be particularly significant, namely: HIF-1, Gfi-1, nuclear factor TG-interacting factor (TGIF) and erythroid transcription factor (GATA-1).

HIF-1 is a regulatory heterodimer consisting of two subunits; HIF-1β is constitutively expressed in all conditions, whereas HIF-1α is rapidly degraded under normal conditions but is stabilized under hypoxia ([@b64]). Despite an average up-regulation of this protein (HIF-1α) by ∼30% in our dataset, our initial screening for cancer gene markers did not reveal this protein because the expression change was too small to be selected. From our microarray findings, the up-regulation of this protein did not result in a systematic activation of gene clusters with a specific function. However, the fact that HIF-1 binding sites were found to be enriched in some down-regulated genes that belonged to the cellular defense response gene ontology term ([Table 4](#tbl4){ref-type="table"}), suggested that this protein might be one of the cellular components responsible for the suppression of the defense response of hypoxic cancer cells. Other genes related to growth factor, protease and apoptosis pathways, e.g. epidermal growth factor receptor, carbonic anhydrase IX, p53-, matrix metalloproteinase 9, that were known to be dependent on HIF-1α for their activation ([@b65]) had fold changes of 2.41, 2.8, 6.5 and 2.51, respectively, in our dataset.

Gfi-1 is a zinc finger protein that binds DNA and functions as a transcriptional repressor through its unique repressor domain, SNAG ([@b66]). In our arrays, this gene was down-regulated in adenocarcinoma cells by an average of 69%, and it was observed that genes that contain activation sites for Gfi-1 were mostly up-regulated in adenocarcinoma cells. One example is the pro-apoptotic regulator gene Bax which was up-regulated by 2.3-fold in adenocarcinoma cells but was shown to be down-regulated by Gfi-1 in immortalized T-cell lines and primary transgenic thymocytes ([@b67]).

TGIF is a transcriptional core-repressor that directly associates with Smad (Sma- and Mad-related protein) proteins and inhibits Smad-mediated transcriptional activation ([@b68]). The gene responses activated by Smad underlie both proliferative and anti-proliferative events that contribute to cancer ([@b69],[@b70]). Originally, TGIF was isolated as a ubiquitously expressed homeodomain protein that can bind to the retinoid X receptor (RXR) response element ([@b71]). Based on our analysis, this gene was up-regulated in lung cancer cells by an average of 2.6-fold while the RXR gene was repressed by an average of 25%.

GATA-1 is a factor that had been shown to be important in the regulation of globin and non-globin genes in erythroid, megakaryocytic and mast cell lineages ([@b72]). From our arrays, this gene was down-regulated by an average of ∼40% in cancer cells. This is consistent with our findings that members in globin gene family (α, β and γ) were all repressed in adenocarcinomas, despite their weak association with primary lung cancers ([Table 2](#tbl2){ref-type="table"}).

In conclusion, by investigating the statistical distribution of the functional annotations attached to cancer associated genes (*M*~AD~) derived from lung tissue microarrays, we have identified functions, corresponding to several key biological systems, which are overrepresented in cancer associated genes ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). The congruence of these functions with known cancer cell oncogenic processes suggests the up- or down-regulation of genes in *M*~AD~ is linked to cancer-related metabolism processes. Subsequently, we clustered the genes in *M*~AD~ into putatively co-regulated gene sets by assuming that co-regulated genes will share common functional roles and exhibit very similar expression profiles. Conserved DNA segments in the upstream regions of these putatively co-regulated gene sets were found and transcription factors that recognize these DNA regions were identified ([Table 4](#tbl4){ref-type="table"}). A literature search on these transcription factors, which are putative regulatory factors in adenocarcinoma development, substantiated that the majority had been previously documented experimentally to be oncogenic transcription factors. These transcription factors, together with their conserved binding sites, suggest new candidates for therapeutic intervention in the treatment of lung adenocarcinomas.

SUPPLEMENTARY MATERIAL
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![Histogram of the cancer associated genes (*M*~AD~) correlation to the tissue labels (normal or lung adenocarcinomas). The average histograms generated from 10 separate random permutations of the cancer labels in the original lung adenocarcinoma dataset is also displayed.](gki188f1){#fig1}

###### 

Genes that were identified to be down- or up-regulated in adenocarcinomas

  Gene description (Gene down-regulated in lung AD)                                                                                              Probe set      Fold log(AD/N)   Mean expression for normal lung   Mean expression for AD lung
  ---------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------- --------------------------------- -----------------------------
  Consensus sequence for Homo sapiens mRNA for receptor for Advanced Glycation End Product (RAGE)                                                217046_s\_at   −5.523           942.82                            20.51
  Homo sapiens fatty acid binding protein 4, adipocyte (FABP4)                                                                                   203980_at      −4.768           3365.42                           123.48
  Human alpha-globin gene with flanks                                                                                                            217414_x\_at   −4.419           9787.41                           457.42
  Homo sapiens mRNA; cDNA DKFZp564N0582 (from clone DKFZp564N0582)                                                                               209074_s\_at   −4.294           678.28                            34.58
  Homo sapiens carbonic anhydrase IV (CA4)                                                                                                       206208_at      −4.276           275.78                            14.24
  Homo sapiens RAGE mRNA for advanced glycation endproducts receptor, whole CDS                                                                  210081_at      −4.261           1593.08                           83.06
  Homo sapiens ficolin (collagen fibrinogen domain-containing) 3 (Hakata antigen) (FCN3)                                                         205866_at      −4.166           1790.33                           99.70
  Human sickle cell beta-globin mRNA                                                                                                             209116_x\_at   −4.155           14733.26                          827.29
  Consensus includes gb:BF939489                                                                                                                 209469_at      −4.028           330.68                            20.27
  Homo sapiens hemoglobin, gamma A (HBG1)                                                                                                        204848_x\_at   −3.922           264.79                            17.47
  Homo sapiens adipose specific 2 (APM2)                                                                                                         203571_s\_at   −3.898           3042.43                           204.08
  Homo sapiens hypothetical protein FLJ10970 (FLJ10970)                                                                                          219230_at      −3.884           1521.30                           103.06
  Consensus includes gb:T50399/UG=Hs.251577 hemoglobin, alpha 1                                                                                  214414_x\_at   −3.874           13447.88                          917.38
  Homo sapiens colony stimulating factor 3 (granulocyte) (CSF3)                                                                                  207442_at      −3.873           145.31                            9.92
  Homo sapiens mutant beta-globin (HBB) gene                                                                                                     217232_x\_at   −3.864           15087.91                          1036.22
  Gene description (Gene up-regulated in lung AD)                                                                                                Probe Set      Fold log(AD/N)                                     
  Homo sapiens XAGE-1 protein (XAGE-1)                                                                                                           220057_at      7.311            4.79                              760.58
  Human alpha-1 type XI collagen (COL11A1)                                                                                                       37892_at       6.208            6.10                              451.07
  Consensus includes gb:AI697108;/UG=Hs.102482 mucin 5, subtype B, tracheobronchial                                                              213432_at      6.192            4.84                              354.11
  Homo sapiens dipeptidyl peptidase IV (DPP4)                                                                                                    203716_s\_at   5.932            6.81                              415.78
  Consensus includes gb:AU159942;/UG=Hs.156346 topoisomerase (DNA) II alpha (170 kDa)                                                            201291_s\_at   5.620            3.24                              159.61
  Homo sapiens serine protease inhibitor, Kazal type 1 (SPINK1);/UG=Hs.181286 serine protease inhibitor, Kazal type 1                            206239_s\_at   5.274            51.74                             2002.30
  Consensus includes gb:X98568;/UG=Hs.179729 collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)                                     217428_s\_at   4.991            21.98                             698.84
  Consensus includes gb:AW192795;/UG=Hs.103707 apomucin                                                                                          214303_x\_at   4.969            5.26                              164.65
  Human nephropontin mRNA;/UG=Hs.313 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)               209875_s\_at   4.851            121.29                            3499.34
  Homo sapiens matrix metalloproteinase 1 (interstitial collagenase) (MMP1)                                                                      204475_at      4.806            25.07                             701.09
  Homo sapiens neuromedin U (NMU)                                                                                                                206023_at      4.776            5.80                              158.88
  Homo sapiens cytokine receptor-like factor 1 (CRLF1)                                                                                           206315_at      4.737            14.22                             379.16
  Homo sapiens, serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3                                                         209720_s\_at   4.597            2.13                              51.63
  Homo sapiens multidrug resistance-associated protein homolog MRP3 (MRP3);/UG=Hs.90786 ATP-binding cassette, sub-family C (CFTRMRP), member 3   209641_s\_at   4.570            14.73                             350.01
  Consensus includes gb:BE791251;/UG=Hs.25640 claudin 3                                                                                          203953_s\_at   4.462            6.82                              150.39

The description of each gene, its probe set in HG-U133A GeneChip and log fold change are given in the table. The complete table can be downloaded at <http://bioinfo.hku.hk/~daniely/lung_microarray>.

###### 

The gene ontology terms overrepresented in the set of genes down-regulated by at least 2-fold in adenocarcinomas

  Annotation term                                            Total   Found   Expected   *P*-value
  ---------------------------------------------------------- ------- ------- ---------- -----------
  GeneOntology terms                                                                    
      Globin                                                 17      12      0.0E+00    0.0E+00
      Rhodopsin-like receptor activity                       384     49      3.8E−04    1.0E−06
      G-protein chemoattractant receptor activity            34      8       2.8E−02    8.4E−04
      Peptide receptor activity                              139     23      1.7E−03    1.2E−05
      G-protein-coupled receptor binding                     52      21      0.0E+00    0.0E+00
      Defense/immunity protein activity                      230     39      0.0E+00    0.0E+00
      Antimicrobial peptide activity                         32      8       1.7E−02    5.4E−04
      Complement activity                                    32      8       1.7E−02    5.4E−04
      Signal transducer activity                             2558    253     0.0E+00    0.0E+00
      Receptor activity                                      1542    162     0.0E+00    0.0E+00
      Transmembrane receptor activity                        1083    121     0.0E+00    0.0E+00
      G-protein coupled receptor activity                    467     61      0.0E+00    0.0E+00
      Chemokine receptor activity                            34      8       2.8E−02    8.4E−04
      Receptor binding                                       592     72      0.0E+00    0.0E+00
      Cytokine activity                                      253     39      0.0E+00    0.0E+00
      Heavy metal binding                                    23      8       9.4E−04    4.1E−05
      Sugar binding                                          132     28      0.0E+00    0.0E+00
      Extracellular                                          1085    138     0.0E+00    0.0E+00
      Extracellular space                                    457     72      0.0E+00    0.0E+00
      Hemoglobin complex                                     18      12      0.0E+00    0.0E+00
      Plasma membrane                                        2297    219     0.0E+00    0.0E+00
      Integral to plasma membrane                            1702    176     0.0E+00    0.0E+00
      Oxygen and reactive oxygen species metabolism          65      15      4.6E−04    7.0E−06
      Calcium ion homeostasis                                26      8       2.9E−03    1.1E−04
      Cell motility                                          414     50      1.2E−03    3.0E−06
      Chemotaxis                                             133     39      0.0E+00    0.0E+00
      Muscle contraction                                     202     25      1.3E−01    6.2E−04
      Response to stress                                     1025    143     0.0E+00    0.0E+00
      Defense response                                       1031    169     0.0E+00    0.0E+00
      Inflammatory response                                  218     50      0.0E+00    0.0E+00
      Immune response                                        950     153     0.0E+00    0.0E+00
      Humoral immune response                                235     38      0.0E+00    0.0E+00
      Antimicrobial humoral response (sensu Invertebrata)    145     24      1.2E−03    8.0E−06
      Cellular defense response                              139     45      0.0E+00    0.0E+00
      Cell communication                                     3667    326     0.0E+00    0.0E+00
      Cell adhesion                                          658     84      0.0E+00    0.0E+00
      Heterophilic cell adhesion                             97      20      9.7E−05    1.0E−06
      Signal transduction                                    2947    254     0.0E+00    0.0E+00
      Cell surface receptor linked signal transduction       1124    117     0.0E+00    0.0E+00
      G-protein coupled receptor protein signaling pathway   657     77      0.0E+00    0.0E+00
      Cytosolic calcium ion concentration elevation          49      10      3.2E−02    6.5E−04
      Cell-cell signaling                                    689     64      3.7E−01    5.4E−04
      Development                                            1920    150     1.5E+00    8.1E−04
      Histogenesis and organogenesis                         125     18      7.5E−02    6.0E−04
      Muscle development                                     167     27      5.0E−04    3.0E−06
      Respiratory gaseous exchange                           36      11      2.2E−04    6.0E−06
      Chemokine activity                                     52      21      0.0E+00    0.0E+00
      Circulation                                            142     22      7.2E−03    5.1E−05
      Peptide receptor activity/G-protein coupled            139     23      1.7E−03    1.2E−05
      Response to external stimulus                          1591    210     0.0E+00    0.0E+00
      Response to biotic stimulus                            1126    179     0.0E+00    0.0E+00
      Response to wounding                                   356     91      0.0E+00    0.0E+00
      Response to pest/pathogen/parasite                     596     123     0.0E+00    0.0E+00
      Response to bacteria                                   19      6       1.3E−02    7.1E−04
      Response to abiotic stimulus                           577     71      0.0E+00    0.0E+00
      Morphogenesis                                          1119    101     4.9E−02    4.4E−05
      Organogenesis                                          1029    91      2.2E−01    2.2E−04
      Cellular process                                       7140    534     0.0E+00    0.0E+00
      Membrane                                               4225    356     0.0E+00    0.0E+00
      Integral to membrane                                   3220    281     0.0E+00    0.0E+00
      Cell growth                                            97      17      7.3E−03    7.5E−05
      Humoral defense mechanism (sensu Invertebrata)         145     24      1.2E−03    8.0E−06
      Cell--cell adhesion                                    220     30      6.8E−03    3.1E−05
      Antimicrobial humoral response                         145     24      1.2E−03    8.0E−06
      Cytolysis                                              20      8       2.4E−04    1.2E−05
      Cytokine binding                                       80      14      2.6E−02    3.2E−04
      Chemokine binding                                      34      8       2.8E−02    8.4E−04
      Carbohydrate binding                                   133     28      0.0E+00    0.0E+00
      Chemoattractant activity                               52      21      0.0E+00    0.0E+00
      Response to chemical substance                         206     48      0.0E+00    0.0E+00
      Peptide binding                                        213     26      1.3E−01    6.1E−04
      Taxis                                                  133     39      0.0E+00    0.0E+00
      Chemokine receptor binding                             52      21      0.0E+00    0.0E+00
      Innate immune response                                 220     50      0.0E+00    0.0E+00
      Eicosanoid biosynthesis                                25      7       1.4E−02    5.7E−04
  Protein domain                                                                        
      Vertebrate metallothionein                             12      7       2.4E−05    2.0E−06
      Aspartic acid and asparagine hydroxylation site        143     21      3.5E−02    2.5E−04
      Rhodopsin-like GPCR superfamily                        289     42      0.0E+00    0.0E+00
      Endothelin receptor                                    6       4       1.3E−03    2.1E−04
      Small chemokine, C-C subfamily                         26      11      0.0E+00    0.0E+00
      Fos transforming protein                               13      6       9.5E−04    7.3E−05
      Thrombospondin, type I                                 52      13      7.8E−04    1.5E−05
      Globin                                                 16      12      0.0E+00    0.0E+00
      Small chemokine, C-X-C subfamily                       18      6       1.1E−02    6.0E−04
      C-type lectin                                          95      19      5.7E−04    6.0E−06
      Alpha crystallin                                       8       4       7.2E−03    9.0E−04
      Myelin proteolipid protein (PLP)                       7       6       0.0E+00    0.0E+00
      Zn-binding protein, LIM                                95      18      2.2E−03    2.3E−05
      Small chemokine, interleukin-8 like                    48      20      0.0E+00    0.0E+00
      EGF-like calcium-binding                               147     21      5.3E−02    3.6E−04
      Heat shock protein Hsp20                               8       4       7.2E−03    9.0E−04
      Fibrinogen, beta/gamma chain, C-terminal globular      38      10      3.4E−03    8.9E−05
      P2 purinoceptor                                        21      7       4.3E−03    2.1E−04
      Myoglobin                                              9       6       3.6E−05    4.0E−06
      Beta haemoglobin                                       8       7       0.0E+00    0.0E+00
      Alpha haemoglobin                                      6       5       3.6E−05    6.0E−06
      Pi haemoglobin                                         6       5       3.6E−05    6.0E−06
      Small chemokine, C-X-C/Interleukin 8                   18      8       1.1E−04    6.0E−06
      Metallothionein superfamily                            12      7       2.4E−05    2.0E−06
      Orphan nuclear receptor                                9       5       9.1E−04    1.0E−04
      Immunoglobulin C-2 type                                223     31      6.2E−03    2.8E−05
      Immunoglobulin subtype                                 368     48      3.7E−04    1.0E−06
      PMP-22/EMP/MP20 family                                 8       4       7.2E−03    9.0E−04
      L1 transposable element                                8       4       7.2E−03    9.0E−04
      EGF-like domain                                        431     46      1.4E−01    3.3E−04
      Type I EGF                                             169     23      6.7E−02    4.0E−04
      AIG1 family                                            6       4       1.3E−03    2.1E−04
      BRICHOS domain                                         13      8       0.0E+00    0.0E+00
      Immunoglobulin-like                                    678     75      6.8E−04    1.0E−06
      LST-1                                                  6       6       0.0E+00    0.0E+00
      Thrombospondin, subtype 1                              27      8       5.0E−03    1.8E−04
      Saposin-like type B, 2                                 7       5       1.3E−04    1.9E−05
      Saposin B                                              12      5       6.5E−03    5.4E−04
  Pathway                                                                               
      GPCRs_Class_A\_Rhodopsin-like                          212     34      0.0E+00    0.0E+00
      Peptide_GPCRs                                          88      20      0.0E+00    0.0E+00
      MAP00590//Prostaglandin and leukotriene metabolism     41      9       3.2E−02    7.7E−04
      GPCRs_Class_B\_Secretin-like                           34      10      9.2E−04    2.7E−05
  Chromosomal location                                                                  
      12p                                                    301     32      2.4E−01    8.1E−04
      8p21                                                   117     18      1.8E−02    1.5E−04
      17q23                                                  68      14      2.2E−03    3.2E−05
      16q13                                                  37      12      3.7E−05    1.0E−06

For each gene ontology term, the total number of genes with this term in the HG-U133A GeneChip, the total number of genes carrying that term in *M*~AD~, the *P*-value of this and the expected number of genes are tabulated. The member genes for each gene ontology term can be downloaded at <http://bioinfo.hku.hk/~daniely/lung_microarray>.

###### 

The gene ontology terms overrepresented in the set of genes up-regulated by at least 2-fold in adenocarcinomas

  Annotation term                                        Total   Found   Expected   *P*-value
  ------------------------------------------------------ ------- ------- ---------- -----------
  Gene Ontology term                                                                
      DNA replication and chromosome cycle               233     54      0.0E+00    0.0E+00
      Cell cycle checkpoint                              50      17      5.5E−04    1.1E−05
      S phase of mitotic cell cycle                      183     38      1.1E−02    6.1E−05
      M phase of mitotic cell cycle                      149     46      0.0E+00    0.0E+00
      Nucleotide binding                                 1737    235     2.1E−01    1.2E−04
      Mitotic cell cycle                                 421     97      0.0E+00    0.0E+00
      M phase                                            201     52      0.0E+00    0.0E+00
      Nuclear division                                   195     50      0.0E+00    0.0E+00
      Chromatin                                          117     29      1.8E−03    1.5E−05
      Nucleosome                                         60      16      3.0E−02    5.0E−04
      Cytokinesis                                        85      24      6.8E−04    8.0E−06
      Catalytic activity                                 4887    638     0.0E+00    0.0E+00
      Carboxypeptidase A activity                        18      8       5.5E−03    3.1E−04
      Extracellular matrix structural constituent        89      21      4.0E−02    4.5E−04
      Collagen                                           54      23      0.0E+00    0.0E+00
      ATP binding                                        1280    177     4.0E−01    3.1E−04
      Extracellular matrix                               345     65      2.1E−03    6.0E−06
      Collagen                                           59      24      0.0E+00    0.0E+00
      Fibrillar collagen                                 23      14      0.0E+00    0.0E+00
      Chromosome                                         147     32      1.3E−02    8.8E−05
      Spindle                                            64      21      1.3E−04    2.0E−06
      Intermediate filament                              76      19      2.9E−02    3.8E−04
      DNA metabolism                                     606     97      3.1E−02    5.1E−05
      DNA replication                                    178     36      2.9E−02    1.6E−04
      DNA dependent DNA replication                      94      23      1.3E−02    1.4E−04
      DNA replication initiation                         25      11      6.3E−04    2.5E−05
      Amino acid and derivative metabolism               240     54      0.0E+00    0.0E+00
      Amino acid metabolism                              197     43      1.2E−03    6.0E−06
      Oncogenesis                                        521     84      6.6E−02    1.3E−04
      Cell cycle                                         871     145     0.0E+00    0.0E+00
      Chromosome segregation                             35      11      2.9E−02    8.4E−04
      Mitosis                                            145     45      0.0E+00    0.0E+00
      Regulation of mitosis                              35      12      6.9E−03    2.0E−04
      Mitotic checkpoint                                 16      7       1.3E−02    8.3E−04
      Ectoderm development                               98      26      1.1E−03    1.1E−05
      Cell proliferation                                 1356    190     1.2E−01    8.9E−05
      Epidermal differentiation                          80      22      2.2E−03    2.8E−05
      Glutamine family amino acid metabolism             46      15      2.9E−03    6.3E−05
      Amine metabolism                                   283     60      0.0E+00    0.0E+00
      Histogenesis                                       131     28      4.3E−02    3.3E−04
      Glucuronosyltransferase activity                   18      8       5.5E−03    3.1E−04
      Transferase activity                               1634    224     1.3E−01    8.1E−05
      Transferase activitytransferring glycosyl groups   225     42      7.0E−02    3.1E−04
      Transferase activitytransferring hexosyl groups    148     34      2.5E−03    1.7E−05
      Other carbon--nitrogen ligase activity             25      9       2.1E−02    8.3E−04
      Purine nucleotide binding                          1723    233     2.3E−01    1.4E−04
      Adenyl nucleotide binding                          1292    179     3.4E−01    2.6E−04
      Intermediate filament cytoskeleton                 76      19      2.9E−02    3.8E−04
  Protein domain                                                                    
      Fibrillar collagen, C-terminal                     23      14      0.0E+00    0.0E+00
      Endoplasmic reticulum targeting sequence           76      19      2.0E−02    2.6E−04
      Epsin N-terminal homology                          16      7       1.1E−02    6.9E−04
      MCM family                                         11      8       2.2E−05    2.0E−06
      Prolyl oligopeptidase                              12      6       8.6E−03    7.1E−04
      Intermediate filament protein                      67      17      3.0E−02    4.4E−04
      von Willebrand factor, type D                      9       6       7.7E−04    8.6E−05
      UDP-glucoronosyl/UDP-glucosyl transferase          15      7       6.4E−03    4.3E−04
      Prolyl endopeptidase, serine active site           8       5       4.4E−03    5.5E−04
      Immunoglobulin V-type                              146     32      6.3E−03    4.3E−05
      Cyclin, C-terminal                                 19      9       1.0E−03    5.4E−05
      Disulphide isomerase                               12      7       8.4E−04    7.0E−05
      Cyclin                                             44      14      4.7E−03    1.1E−04
      Cyclin, N-terminal domain                          34      12      3.7E−03    1.1E−04
      Histone core                                       25      9       1.7E−02    6.7E−04
      Collagen triple helix repeat                       106     28      3.2E−04    3.0E−06
      Collagen helix repeat                              69      22      6.9E−05    1.0E−06
  Pathway                                                                           
      Cell_cycle                                         133     43      5.7E+00    4.3E−02
      Glutamate_metabolism                               27      12      3.2E−01    1.2E−02
      MAP00251//glutamate metabolism                     43      15      6.5E−01    1.5E−02
      Androgen_and_estrogen_metabolism                   15      7       1.1E−01    7.0E−03
      MAP00150//androgen and estrogen metabolism         32      11      3.5E−01    1.1E−02
  Chromosomal location                                                              
      7                                                  961     129     8.7E−01    9.1E−04
      1q                                                 920     126     4.4E−01    4.8E−04
      8q                                                 388     67      5.8E−03    1.5E−05

Details are as described in [Table 2](#tbl2){ref-type="table"}.

###### 

Highly conserved DNA regions, detected with MoDEL, in regions 5 kb directly upstream of the transcription start site in putatively co-regulated gene sets

  Gene Ontology                                                                                                              Location[b](#tf4-2){ref-type="table-fn"}   Frequency[c](#tf4-3){ref-type="table-fn"}   Similar regulation[d](#tf4-4){ref-type="table-fn"}   Putative transcription factors[e](#tf4-5){ref-type="table-fn"}
  --------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------ ------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------
  Gene up-regulated in lung adenocarcinomas cells                                                                                                                                                                                                                        
                                                      DNA replication and chromosome cycle[a](#tf4-1){ref-type="table-fn"}                                                                                                                                               
  NM 004526                                           `gggcgt GGTGGCTCACGCCTGTAATCCTAGCACTATGGGAGGCCAAGGCAGGCGGAt ccact`     −2467                                      1                                           100%                                                 Whn,AhR,GATA-1,PITX2,HIF-1
  NM 002916                                           `aggcac GGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGAt gccga`     −2920                                      7                                           75%                                                  MyoD,E47,AREB6,E12,USF,GATA-1,PITX2
  NM 003504                                           `gggtgc GGTGGCTCACGCCTATAATCCCAGCACTTTGGGAGGCAGAGGCAGGTGGA ttacct`     −3179                                      1                                           100%                                                 Whn,AhR,GATA-1,PITX2,Major,MyoD,E47,TFII-I,AREB6,TAL1,E12,USF,HIF-1
  Profile                                             `RGGYRY GGTGGCTCACRCCTRTAATCCYAGCACTWTGGGAGGCMRAGGYRGGYGGA TBMMSW`                                                                                                                                                 
                                                      Nuclear division[a](#tf4-1){ref-type="table-fn"}                                                                                                                                                                   
  NM 004701                                           `agtagt CCCAGCTACTCGGGTGGCTGAGGTAGGAGGATCACTTGAGCCCGGGGGAT tgaggc`     −3735                                      1                                           100%                                                 HES1,SREBP-1,TFII-I,DEC,USF,Nkx2-5,GATA-1
  NM 001211                                           `tatagt CCCAGCTACATGGGAGGATGAGGCAGGAAGATCGCTTGAACCTGGGAGGT ggaggt`     −3705                                      1                                           100%                                                 TFII-I,Elk-1,NERF1a,c-Ets-1(p54),68,AREB6
  NM 020242                                           `tgtagt CCCAGCTGCTTGAGAGGCTGAGGCAGGAGGATCACTTGAGCCCAGGAGGT caaggc`     −2016                                      1                                           100%                                                 TAL1,HEB,TFII-I,Zta,c-Ets-1(p54),DEC,SREBP-1,USF,Nkx2-5,RORalpha1
  NM 022346                                           `ctgtaa CCCAGCTACTTGGGAGACTGAGGCGGGAGAATCGCTTCAACCCGGGAGGC agaggt`     −2071                                      1                                           100%                                                 
  NM 003981                                           `tgtaat CTGAGCTACTTGGGAGGCTGAAGCAGGAGAATCACTTGAACCTGGGAGGC ggaggt`     −866                                       1                                           100%                                                 TFII-I,DEC,Nkx2-2,SREBP-1,USF,Nkx2-5,AREB6,HIF-1
  NM 001237                                           `ttgaac TGCAAGAACAGCCGCCGCTCCGGCGGGCTGCTCGCTGCATCTCTGGGCGT ctttgg`     −167                                       1                                           100%                                                 
  NM 001813                                           `tgtaat CCCAGCTACTGGGGAGGCTGAGGCAGGAGAATCACTTGAATGCAGGAGGT ggaggc`     −715                                       1                                           100%                                                 TFII-I,Zta,DEC,Nkx2-2,SREBP-1,USF,TTF1,Nkx2-5,c-Ets-1,c-Ets-1(p54),AREB6
  NM 002358                                           `tgtagt CTCAGCTACTTGGGAGTCCGAGGCAGGAGAATTGCTTGAACCTGGGAGGC agaggt`     −4881                                      1                                           100%                                                 TFII-I,C/EBPdelta,AREB6
  NM 022346                                           `ctgtaa CCCAGCTACTTGGGAGACTGAGGCGGGAGAATCGCTTCAACCCGGGAGGC agaggt`     −2071                                      1                                           100%                                                 
  Profile                                             `HDKWRH YBSARSWRCWBSVGHSDMYSMRGYRGGMDRMTYRCTKSADYBYDGGRSRY NDWKGB`                                                                                                                                                 
  Gene down-regulated in lung adenocarcinomas cells                                                                                                                                                                                                                      
                                                      Cellular defense response[a](#tf4-1){ref-type="table-fn"}                                                                                                                                                          
  NM 005874                                           `cttgat GGTCCCGGGACCCTGTGGCATCTCACCTCTGGCCTCTGTTCTTTCTTGTG agtccg`     −715                                       1                                           100%                                                 USF,AREB6,GR
  NM 000265                                           `tggcag GATCTCGGCTCACTGCAACCTCCACCTCCCTGGTTCAAGTGATTCTCCTG tcttac`     −3997                                      2                                           100%                                                 RFX1,TFII-I,AREB6,DEC,SREBP-1,Nkx2-2,Nkx2-5,USF, HIF-1
  NM 016382                                           `tggcgt GATCTCGGCTCACTGCAACCTCCACCTCCTGGATTCAAGTGATTCTCCTG cctcag`     −3907                                      1                                           100%                                                 RFX1,TFII-I,AREB6,c-Ets-1(p54),GATA-1,DEC,TTF1,SREBP-1,Nkx2-2,Nkx2-5,USF,Zta
  Profile                                             `YKKSRK GRTCYCGGSWCMCTGYRRCMTCYMMCYYCYKGVYTCWRKTSWTTCTYSTG HSTYMS`                                                                                                                                                 
                                                      Signal transduction[a](#tf4-1){ref-type="table-fn"}                                                                                                                                                                
  NM 000459                                           `tcagga GGCTGAGGCAGAAGAATCGCTTGAACCCAGGAGGCGGACGTTGCAGTGAG ccgaga`     −2597                                      1                                           100%                                                 Zta,c-Ets-1(p54),RFX1
  NM 005308                                           `ttggga GGCTGAAGTACAAGAATCATTTGAACCTGGGAGGCCGAGGTTGCAGTGAG ccgaga`     −2401                                      1                                           100%                                                 GATA-1,AREB6,RFX1
  NM 000115                                           `ttggga GGCTGAGGCAGGAGAATCACTTGAACCTGGGAGCCGGAGGTTGCAGTGAG ctgaga`     −1967                                      2                                           50%                                                  TFII-I,Zta,DEC,SREBP-1,Nkx2-2,USF,Nkx2-5,AREB6,c-Ets-1(p54)
  NM 005424                                           `gccagt GGTGGCAAGAGGTGGAGCAACGGGTGCCAGGGCAGGGAGAGGTGAGTCTG ggaggg`     −1039                                      1                                           100%                                                 AREB6,v-Myb,MAZ,Hand1:E47
  NM 003991                                           `tgggcg CGCTGCGGGAGCTGTAGCTCAGCCAGCCAGGGAGTAGCGGCTTTCATCCG ccggga`     −340                                       1                                           100%                                                 SMAD-3
  NM 005795                                           `ttggga GGTTGAGGCAGGAGAATTGCTTGAACCCGGGAGGTGGAGGTTGCAGTGAG ctgaga`     −1930                                      1                                           100%                                                 Zta,TFII-I,C/EBPdelta,c-Ets-1(p54),AREB6
  NM 003357                                           `ttggga GGCTGAGGCAGGAGAATCGTCTGAACTCGGGAGGTGGAGGTTGCAGTGAG ccgctg`     −4624                                      1                                           100%                                                 Zta,TFII-I,c-Ets-1(p54),AREB6,RFX1
  NM 005856                                           `ttgtga GGCTGAGGCAGGAGAATCGCTTGAATCCAGGAGGTGGAGGTTGCAGTGAG ccggga`     −3601                                      3                                           100%                                                 Zta,TFII-I,GATA-1,c-Ets-1(p54),AREB6,RFX1
  NM 004844                                           `acagga GGCTGAGGCAGGAGAATAGCTTGAACCCAGGAGGCGGAGGTTGCAGTGAG ctaaca`     −4824                                      3                                           100%                                                 Zta,TFII-I,c-Ets-1(p54)
  Profile                                             `DBVDSD SGYKGMRRBASVWGDAKHDHHKSVWBYYRGGRVVBVGMSRBKKBMRTSHG SBRVBR`                                                                                                                                                 

The complete table can be downloaded at <http://bioinfo.hku.hk/~daniely/lung_microarray>.

^a^Overrepresented gene ontology terms.

^b^Location of conserved sequence upstream of the transcription start site.

^c^Frequency of occurrence of conserved sequence in 5 kb upstream regions of genes given in ([@b32]).

^d^Percentage of the genes with a matched upstream sequence and their expression trends.

^e^Transcription factor name from TRANSFAC (8.3) FACTOR table ([@b35],[@b73]).
